The Influence of HIV-1 Subtype in the Response to Therapeutic Dendritic Cell Vaccine.

Q3 Medicine

Open AIDS Journal Pub Date : 2012-01-01 Epub Date: 2012-12-14 DOI:10.2174/1874613601206010289

Valéria Ferreira, Patrícia Moura, Sergio Crovella, Ricardo Sobhie Diaz, Adauto Castelo Filho, Ricardo Ximenes, Luiz Cláudio Arraes

{"title":"The Influence of HIV-1 Subtype in the Response to Therapeutic Dendritic Cell Vaccine.","authors":"Valéria Ferreira, Patrícia Moura, Sergio Crovella, Ricardo Sobhie Diaz, Adauto Castelo Filho, Ricardo Ximenes, Luiz Cláudio Arraes","doi":"10.2174/1874613601206010289","DOIUrl":null,"url":null,"abstract":"<p><p>In the present study, we investigated the influence of HIV-1 subtype in the response to the dendritic cell (DC) therapeutic vaccine for HIV. HIV-1 viral load and TCD8+/TCD4+ cell counts for up to 48 weeks after vaccination. Out of 19 immunized subjects, 13 were infected by subtype B, 5 by subtype F, and 1 by subtype D. Overall, 42.1% (8/19) achieved a viral load decline of ≥ 1 log(10) sustained up to 48 weeks after immunization. Such magnitude of viral load drop was seen in 80% (4/5) of subtype F infected patients, and in 23.0% (3/13) of the subtype B infected ones (p=0.08). Moreover, mean viral load decline was 1.32 log(10), for subtype F infected individuals compared to 0.5 log(10) among subtype B infected patients (p=0.01). The variation in TCD4+ cell count was not related to HIV-1 subtype. Larger studies are necessary to confirm the efficacy of this immunotherapy and the differential response according to the background genetic diversity of HIV-1.</p>","PeriodicalId":53617,"journal":{"name":"Open AIDS Journal","volume":" ","pages":"289-92"},"PeriodicalIF":0.0000,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4f/2d/TOAIDJ-6-289.PMC3534477.pdf","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open AIDS Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1874613601206010289","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2012/12/14 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 6

Abstract

In the present study, we investigated the influence of HIV-1 subtype in the response to the dendritic cell (DC) therapeutic vaccine for HIV. HIV-1 viral load and TCD8+/TCD4+ cell counts for up to 48 weeks after vaccination. Out of 19 immunized subjects, 13 were infected by subtype B, 5 by subtype F, and 1 by subtype D. Overall, 42.1% (8/19) achieved a viral load decline of ≥ 1 log(10) sustained up to 48 weeks after immunization. Such magnitude of viral load drop was seen in 80% (4/5) of subtype F infected patients, and in 23.0% (3/13) of the subtype B infected ones (p=0.08). Moreover, mean viral load decline was 1.32 log(10), for subtype F infected individuals compared to 0.5 log(10) among subtype B infected patients (p=0.01). The variation in TCD4+ cell count was not related to HIV-1 subtype. Larger studies are necessary to confirm the efficacy of this immunotherapy and the differential response according to the background genetic diversity of HIV-1.

Abstract Image

查看原文本刊更多论文

HIV-1亚型在治疗性树突状细胞疫苗应答中的影响

在本研究中，我们研究了HIV-1亚型对树突状细胞(DC)治疗性HIV疫苗应答的影响。疫苗接种后48周的HIV-1病毒载量和TCD8+/TCD4+细胞计数。在19名免疫受试者中，13人感染B亚型，5人感染F亚型，1人感染d亚型。总体而言，42.1%(8/19)的病毒载量在免疫后48周内持续下降≥1 log(10)。80%(4/5)的F亚型感染者和23.0%(3/13)的B亚型感染者出现这种程度的病毒载量下降(p=0.08)。此外，F亚型感染者的平均病毒载量下降为1.32 log(10)，而B亚型感染者的平均病毒载量下降为0.5 log(10) (p=0.01)。TCD4+细胞计数的变化与HIV-1亚型无关。需要更大规模的研究来证实这种免疫疗法的疗效和根据HIV-1背景遗传多样性的差异反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Open AIDS Journal Medicine-Public Health, Environmental and Occupational Health

CiteScore

1.30

自引率

0.00%

发文量